OR WAIT null SECS
Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research
Providing a boost to manufacturing of medical diagnostics in North America, SCHOTT has opened its first US-based facility—a fully integrated microfluidic foundry based in Phoenix, Ariz.
During the COVID-19 pandemic, the demand for fast and efficient diagnostic testing for multiple illnesses has risen significantly. SCHOTT’s focus on microfluidic consumables combined with the US’s growing interest in onshoring manufacturing has helped enable the SCHOTT expansion. Opened by SCHOTT MINIFAB, the almost 40,000-square-foot facility is comprised of a clean room and high-volume manufacturing of microarrays and microfluidic devices.
According to Heinz Kaiser, PhD, a member of SCHOTT’s management board of directors, the US is one of Germany-based SCHOTT’s most vital markets. He believes the Phoenix facility will create a direct line for American consumers to receive more efficient and timely results.
Phoenix will mark SCHOTT’s third diagnostics location, with other centers of excellence located in Jena, Germany, and Melbourne, Australia. The company says this will be the first location to place a special emphasis on bioscience capabilities using high-density microarrays for diagnostic and life science research.